# CLBS119 for Repair of COVID-19 Induced Pulmonary Damage

> **NCT04522817** · PHASE1 · WITHDRAWN · sponsor: **Lisata Therapeutics, Inc.**

## Conditions studied

- Covid-19

## Interventions

- **BIOLOGICAL:** CLBS119

## Key facts

- **NCT ID:** NCT04522817
- **Lead sponsor:** Lisata Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-10-05
- **Primary completion:** 2021-05
- **Final completion:** 2021-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Acute COVID-19 treatments have improved significantly leading to decreased use of ventilatory support. This, coupled with approval of a vaccine, has changed the profile/prognosis of patients and led to a lack of patients with long-term hypoxia.
- **Last updated:** 2024-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04522817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04522817, "CLBS119 for Repair of COVID-19 Induced Pulmonary Damage". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04522817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*